The Circulating Fatty Acid Transporter Soluble CD36 Is Not Associated with Carotid Atherosclerosis in Subjects with Type 1 and Type 2 Diabetes Mellitus

Simple item page
dc.contributor.authorCastelblanco Echavarría, Esmeralda
dc.contributor.authorSanjurjo, Lucía
dc.contributor.authorBarranco Altirriba, María
dc.contributor.authorFalguera, Mireia
dc.contributor.authorHernández García, Marta
dc.contributor.authorSoldevila, Berta
dc.contributor.authorSarrias, Maria-Rosa
dc.contributor.authorFranch-Nadal, Josep
dc.contributor.authorArroyo, Juan Antonio
dc.contributor.authorFernández Real, José Manuel
dc.contributor.authorAlonso, Núria
dc.contributor.authorMauricio Puente, Dídac
dc.date.accessioned2022-02-09T10:28:56Z
dc.date.available2022-02-09T10:28:56Z
dc.date.issued2020
dc.description.abstractThis study aimed to determine the association of fatty acid transporter plasma solublecluster of differentiation 36 (sCD36) with subclinical carotid atherosclerosis (SCA). A cross-sectionalstudy was conducted in 1023 subjects, 225 with type 1 diabetes (T1D), 276 with type 2 diabetes (T2D)and 522 who were nondiabetic. Carotid atherosclerotic plaque (CAP) presence was determined usingB-mode carotid ultrasound imaging. sCD36 were analysed by ELISA, and CD36 surface receptor andmRNA expression were measured by flow cytometry and real-time PCR. Logistic regression modelswere used to evaluate sCD36 as a biomarker of SCA. Up to 376 (36.75%) participants had at least oneCAP, 76 T1D, 164 T2D and 136 without diabetes, while the remaining 647 (63.25%) did not have anyCAP. There were no differences in sCD36 between patients with and without CAP in T1D (p=0.287)or T2D (p=0.513). Although nondiabetic subjects with plaques had lower sCD36 levels than thosewithout (p=0.023), the multivariate models revealed no association of sCD36 with CAP in any of thethree study groups. No differences were found in surface CD36 or CD36 mRNA expression between the patients with and without CAP. sCD36 is not associated with SCA in type 1 or type 2 diabetic orin nondiabetic subjects.ca_ES
dc.description.sponsorshipThis research was supported by grants from the European Foundation for the study of diabetes (2014-EFSD-00914) and European Regional Development Fund (ERDF). CIBER for Diabetes and Associated Metabolic Diseases (CIBERDEM), CIBER on Liver and Digestive Diseases (CIBEREHD), and CIBER on Physiopathology ofObesity and Nutrition (CIBEROBN) are initiatives of the Carlos III National Institute of Health, Spain.ca_ES
dc.identifier.doihttps://doi.org/10.3390/jcm9061700
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/10459.1/72969
dc.language.isoengca_ES
dc.publisherMDPIca_ES
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/jcm9061700ca_ES
dc.relation.ispartofJournal of Clinical Medicine, 2020, vol. 9, núm. 6ca_ES
dc.rightscc-by (c) authors, 2020ca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectAtherosclerotic plaqueca_ES
dc.subjectCarotid atherosclerosisca_ES
dc.subjectsCD36ca_ES
dc.subjectType 1 diabetes mellitusca_ES
dc.subjectType 2diabetes mellitusca_ES
dc.titleThe Circulating Fatty Acid Transporter Soluble CD36 Is Not Associated with Carotid Atherosclerosis in Subjects with Type 1 and Type 2 Diabetes Mellitusca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/publishedVersionca_ES
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
JClinMed_a20v9n6.pdf
Size:
6.36 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Articles publicats (IRBLleida)